David Campbell Email & Phone Number

San Diego, Ca, Us

San Diego, California, Us

Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors have faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations. Janux is developing a broad pipeline with lead programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2), with all of its programs currently in the IND-enabling or discovery stage.

Responsible for the identification, formation and strategic operations of life science portfolio companies including Iron Horse Therapeutics, Adrenergics, Thyritope and Sitari.

Sitari was acquired by GlaxoSmithKline in August 2019, after successfully developing inhibitors of Transglutaminase-2 for the treatment of Celiac Disease.

Developing first-in-class treatments for ALS. Humans with mutations that eliminate or reduce the activity of EphA4 live longer with decreased disease severity. Iron Horse Therapeutics will develop EphA4 antagonists based upon the technology developed in Dr. Maurizio Pellecchia's laboratory at Sanford Burnham Prebys.

Enlibrium is developing novel drugs based on metformin to treat a range of different cancers by reducing cancer energy consumption and reestablishing energy balance. Given their high growth rate and energy requirements, cancers are particularly sensitive to agents that reduce their energy production. Enlibrium was founded based on technology exclusively licensed from UCLA and developed in laboratories headed by Michael Jung, Ph.D. and Richard Pietras, M.D., Ph.D. Enlibrium’s investors are Avalon Ventures, TPG Biotech, Correlation Ventures and Osage University Partners. Enlibrium is located in COI Pharmaceuticals, Avalon’s Community of Innovation, in San Diego.

Developing novel treatments for idiopathic dilated cardiomyopathy.

Developing modulators of thyroid stimulating hormone receptor autoantibodies for the treatment of Graves' Disease.

San Diego, Ca, Us

Us

La Jolla, Ca, Us

Leverkusen, North Rhine-Westphalia, De

Doctor Of Philosophy (Phd), Organic Chemistry

Bachelor'S Degree, Organic Chemistry